Equity Profile

MDGL

Madrigal Pharmaceuticals, Inc.

Health CareBiotechnology$11.5B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Madrigal Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for liver diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

N/A

Revenue

Revenue figures will help assess the company's market performance and growth trajectory.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

MDGL Q2-2026 Earnings Preview

Context

Company Snapshot

Madrigal Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for liver diseases. With a market cap of $11 billion, it plays a crucial role in the health care sector, particularly in addressing unmet medical needs in chronic liver conditions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-932.88%

Avg Stock Reaction

+4.22%

Last Quarter Recap

In Q1-2026, Madrigal reported an EPS of -$3.25, beating estimates by nearly 10%. The stock reacted positively, gaining 7.42% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for its lead drug candidate.
Commitment to improving operational efficiency.
Plans to enhance investor communication regarding pipeline developments.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent performance and history of EPS surprises.

Bull Case

If Madrigal continues to beat EPS estimates and provides positive updates on its drug pipeline, it could see significant stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on clinical trials, the stock could face downward pressure.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the latest update on the clinical trials for the lead drug candidate?

Investors will closely monitor this as it could significantly influence future revenue potential and stock performance.

How does management plan to address the recent fluctuations in EPS?

Understanding management's strategy for improving profitability will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential impact of Madrigal's clinical trial results, which could be more favorable than anticipated.

Supporting Evidence

The company's recent history shows a 75% EPS beat rate, indicating a strong potential for positive surprises.

Options pricing suggests a significant move, which may reflect investor uncertainty not fully captured in consensus estimates.

Key Risk

If clinical trial results exceed expectations, it could invalidate the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on clinical trial outcomes and management's ability to communicate a clear path to profitability.

Bull Confirmed If

A positive update on clinical trial results could lead to a stock price increase of 10% or more.

Bear Confirmed If

If the EPS comes in worse than -$3.50, it could signal deeper issues and lead to a significant drop in stock price.

Pre-Earnings Positioning

Options Market

Implied Move

±25.88%

Historical Avg

±10.5%

Pricing rich

The options market is pricing in a significant potential move, suggesting heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±25.9% while MDGL has averaged ±10.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.7%

Calls (800)P/C Ratio: 0.57Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Madrigal beats expectations and raises guidance, history suggests the stock could rise by about 6.18% on the following day.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience a muted reaction.

Miss

A miss on EPS could lead to a decline of approximately 1.64%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the timeline for clinical trial results.
2Any updates on partnerships or collaborations that could enhance the drug pipeline.
3Management's strategy for addressing recent EPS fluctuations.
4Insights into operational efficiency improvements.
5Future guidance on revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Madrigal Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for liver diseases....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

N/A

Revenue

Revenue figures will help assess the company's market performance and growth trajectory.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

MDGL Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

-932.88%

Avg Stock Reaction

+4.22%

Last Quarter Recap

In Q1-2026, Madrigal reported an EPS of -$3.25, beating estimates by nearly 10%. The stock reacted positively, gaining 7.42% the following day.

Management Promises & Guidance

Focus on advancing clinical trials for its lead drug candidate.
Commitment to improving operational efficiency.
Plans to enhance investor communication regarding pipeline developments.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's recent performance and history of EPS surprises.

Bull Case

If Madrigal continues to beat EPS estimates and provides positive updates on its drug pipeline, it could see significant stock appreciation.

Bear Case

Conversely, if the company fails to meet expectations or provides disappointing updates on clinical trials, the stock could face downward pressure.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the latest update on the clinical trials for the lead drug candidate?

Investors will closely monitor this as it could significantly influence future revenue potential and stock performance.

How does management plan to address the recent fluctuations in EPS?

Understanding management's strategy for improving profitability will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating the potential impact of Madrigal's clinical trial results, which could be more favorable than anticipated.

Supporting Evidence

The company's recent history shows a 75% EPS beat rate, indicating a strong potential for positive surprises.

Options pricing suggests a significant move, which may reflect investor uncertainty not fully captured in consensus estimates.

Key Risk

If clinical trial results exceed expectations, it could invalidate the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on clinical trial outcomes and management's ability to communicate a clear path to profitability.

Bull Confirmed If

A positive update on clinical trial results could lead to a stock price increase of 10% or more.

Bear Confirmed If

If the EPS comes in worse than -$3.50, it could signal deeper issues and lead to a significant drop in stock price.

Pre-Earnings Positioning

Options Market

Implied Move

±25.88%

Historical Avg

±10.5%

Pricing rich

The options market is pricing in a significant potential move, suggesting heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±25.9% while MDGL has averaged ±10.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.7%

Calls (800)P/C Ratio: 0.57Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Madrigal beats expectations and raises guidance, history suggests the stock could rise by about 6.18% on the following day.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may experience a muted reaction.

Miss

A miss on EPS could lead to a decline of approximately 1.64%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the timeline for clinical trial results.
2Any updates on partnerships or collaborations that could enhance the drug pipeline.
3Management's strategy for addressing recent EPS fluctuations.
4Insights into operational efficiency improvements.
5Future guidance on revenue expectations.